Table 2.
Standardized rates and standardized rate ratio between sexes
| Women | Men | |||||
|---|---|---|---|---|---|---|
| Indicators | standardized ratesa | (95 % CI) | standardized ratesa | (95 % CI) | RRb | (95 % CI) |
| Participants from successfully-invited population | 67.14 | (66.67-67.62) | 61.69 | (61.23-62.16) | 0.91 | (0.91-0.92) |
| Lesions among participants | 15.69 | (14.82-16.61) | 48.50 | (46.84-50.20) | 3.07 | (2.96-3.17) |
| Cancer among participants | 2.42 | (2.08-2.80) | 5.79 | (5.22-6.41) | 2.34 | (2.12-2.58) |
| Stage III/IV cancer among participants | 0.82 | (0.63-1.05) | 1.76 | (1.45-2.12) | 2.03 | (1.69-2.43) |
| Colonoscopies performed after + FOBT | 92.07 | (88.99-95.23) | 92.95 | (90.52-95.44) | 1.01 | (0.99-1.04) |
| Lesions identified among colonoscopy patients | 35.30 | (33.33-37.36) | 56.11 | (54.17-58.10) | 1.62 | (1.56-1.67) |
| Lesions, out of those with + FOBT | 32.50 | (30.68-34.40) | 52.19 | (50.39-54.04) | 1.63 | (1.58-1.69) |
aRates per 1000 for lesions, cancer and cancer stage; percentage for participants, colonoscopy after + FOBT and colonoscopy patients with lesions
bStandardized rate ratio for men/women